Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00878709 | Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer(ExteNET) | completed | Phase 3 | 2,840 | Puma Biotechnology, Inc.INDUSTRY | 40 | Jun 11, 2021 | clinicaltrials |
| NCT02518191 | Effects of GnRHa on Ovarian Function Against Chemotherapy-induced-gonadotoxicity | completed | Phase 3 | 345 | Xiangyun ZongOTHER | 1 | Jun 11, 2021 | clinicaltrials |
| NCT01492101 | The BEACON Study (Breast Cancer Outcomes With NKTR-102)(BEACON) | completed | Phase 3 | 852 | Nektar TherapeuticsINDUSTRY | 11 | Jun 1, 2021 | clinicaltrials |
| NCT04718324 | PREMs on PROMs in Breast Disease (PREMs_PROMs)(PREMs_PROMs) | completed | Phase 3 | 230 | Uppsala UniversityOTHER | 1 | May 17, 2021 | clinicaltrials |
| NCT02872103 | Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy | completed | Phase 3 | 122 | EVIVE BiotechnologyINDUSTRY | 1 | May 5, 2021 | clinicaltrials |
| NCT00004067 | Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2 | completed | Phase 3 | 2,130 | NSABP Foundation IncNETWORK | 2 | Apr 29, 2021 | clinicaltrials |
| NCT01566721 | A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer(SafeHER) | completed | Phase 3 | 2,577 | Hoffmann-La RocheINDUSTRY | 59 | Apr 27, 2021 | clinicaltrials |
| NCT00073528 | Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer | completed | Phase 3 | 1,286 | Novartis PharmaceuticalsINDUSTRY | 29 | Feb 24, 2021 | clinicaltrials |
| NCT02324088 | Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer(PEGASE07) | completed | Phase 3 | 174 | UNICANCEROTHER | 0 | Feb 21, 2021 | clinicaltrials |
| NCT01150513 | Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer | completed | Phase 2 / Phase 3 | 320 | Chinese Academy of Medical SciencesOTHER | 1 | Feb 9, 2021 | clinicaltrials |
| NCT00544765 | Docetaxel, Doxorubicin and Cyclophosphamide Versus Vinorelbine and Capecitabine in Patients Not Sufficiently / Sufficiently Responding as Preoperative Treatment of Locally Advanced or Operable Primary Breast Cancer(GeparTrio) | completed | Phase 3 | 2,014 | GBG Forschungs GmbHOTHER | 0 | Feb 4, 2021 | clinicaltrials |
| NCT01690702 | Study of Nab-Paclitaxel in High Risk Early Breast Cancer(GAIN-2) | completed | Phase 3 | 2,886 | GBG Forschungs GmbHOTHER | 1 | Feb 2, 2021 | clinicaltrials |
| NCT01591811 | Prospective Trial of Two Prone Breast Radiotherapy Techniques With Randomization to Concurrent Versus Weekly Boost | completed | Phase 3 | 433 | NYU Langone HealthOTHER | 1 | Jan 19, 2021 | clinicaltrials |
| NCT00075764 | S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer | completed | Phase 3 | 695 | SWOG Cancer Research NetworkNETWORK | 2 | Jan 13, 2021 | clinicaltrials |
| NCT03343145 | A Study to Evaluate the Efficacy, Safety and Immunogenicity of Leucostim® Versus Neupogen® in Breast Cancer Patients | completed | Phase 3 | 143 | Dong-A ST Co., Ltd.INDUSTRY | 1 | Dec 28, 2020 | clinicaltrials |
| NCT01940497 | A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer(SCHEARLY) | completed | Phase 3 | 240 | Hoffmann-La RocheINDUSTRY | 1 | Nov 3, 2020 | clinicaltrials |
| NCT03165149 | Effect of a Topical Ketamine on Acute and Chronic Pain, Dose Finding | completed | Phase 2 / Phase 3 | 90 | Assiut UniversityOTHER | 1 | Nov 3, 2020 | clinicaltrials |
| NCT00080301 | Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer | completed | Phase 3 | 752 | R-PharmINDUSTRY | 22 | Nov 2, 2020 | clinicaltrials |
| NCT00082433 | Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer | completed | Phase 3 | 1,221 | R-PharmINDUSTRY | 29 | Nov 2, 2020 | clinicaltrials |
| NCT00309491 | Randomized Study Comparing Tamoxifen vs. Tamoxifen + Aminoglutethimide in Postmenopausal Receptor-positive Patients | completed | Phase 3 | 2,021 | Austrian Breast & Colorectal Cancer Study GroupNETWORK | 0 | Oct 19, 2020 | clinicaltrials |
| NCT00309569 | Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients | completed | Phase 3 | 429 | Austrian Breast & Colorectal Cancer Study GroupNETWORK | 0 | Oct 14, 2020 | clinicaltrials |
| NCT04237090 | Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel(PREMED-F1) | completed | Phase 3 | 27 | Ciusss de L'Est de l'Île de MontréalOTHER | 1 | Oct 12, 2020 | clinicaltrials |
| NCT00014222 | Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer | completed | Phase 3 | 2,104 | NCIC Clinical Trials GroupNETWORK | 2 | Oct 5, 2020 | clinicaltrials |
| NCT01572038 | A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer(PERUSE) | completed | Phase 3 | 1,436 | Hoffmann-La RocheINDUSTRY | 39 | Sep 25, 2020 | clinicaltrials |
| NCT01610284 | Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor(BELLE-2) | completed | Phase 3 | 1,147 | Novartis PharmaceuticalsINDUSTRY | 29 | Aug 25, 2020 | clinicaltrials |
| NCT00005970 | Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer | completed | Phase 3 | 3,436 | National Cancer Institute (NCI)NIH | 4 | Aug 14, 2020 | clinicaltrials |
| NCT01000662 | Study Comparing Whole Breast Radiotherapy With a Daily Versus a Weekly Tumor | completed | Phase 3 | 412 | NYU Langone HealthOTHER | 1 | Aug 6, 2020 | clinicaltrials |
| NCT01583426 | Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)(GeparSepto) | completed | Phase 3 | 1,229 | GBG Forschungs GmbHOTHER | 1 | Aug 6, 2020 | clinicaltrials |
| NCT00047255 | Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer | completed | Phase 3 | 263 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT00123669 | Primary Progesterone Therapy for Operable Breast Cancer | completed | Phase 2 / Phase 3 | 1,000 | Tata Memorial HospitalOTHER_GOV | 1 | Jul 22, 2020 | clinicaltrials |
| NCT01950182 | Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer(SYSUCC-002) | completed | Phase 3 | 392 | Sun Yat-sen UniversityOTHER | 1 | Jul 15, 2020 | clinicaltrials |
| NCT02429427 | European Celecoxib Trial in Primary Breast Cancer(REACT) | completed | Phase 3 | 2,639 | Imperial College LondonOTHER | 0 | Jun 23, 2020 | clinicaltrials |
| NCT00337103 | E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes | completed | Phase 3 | 1,276 | Eisai Inc.INDUSTRY | 23 | Jun 18, 2020 | clinicaltrials |
| NCT00418457 | Regional Anesthesia and Breast Cancer Recurrence | completed | Phase 3 | 2,108 | The Cleveland ClinicOTHER | 6 | Jun 16, 2020 | clinicaltrials |
| NCT01112826 | Efficacy of Capecitabine Metronomic Chemotherapy to Triple-negative Breast Cancer(SYSUCC-001) | completed | Phase 3 | 443 | Sun Yat-sen UniversityOTHER | 1 | May 27, 2020 | clinicaltrials |
| NCT01216111 | Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN) | completed | Phase 3 | 647 | Fudan UniversityOTHER | 0 | May 19, 2020 | clinicaltrials |
| NCT01026116 | A Randomized Trial Comparing EC-wPversus EP-wP as Adjuvant Therapy for Operable Breast Cancer Patients Less Than 40 Years Old | completed | Phase 3 | 521 | Fudan UniversityOTHER | 1 | May 12, 2020 | clinicaltrials |
| NCT00003088 | Combination Chemotherapy in Treating Patients With Breast Cancer | completed | Phase 3 | 2,005 | Alliance for Clinical Trials in OncologyOTHER | 2 | Apr 29, 2020 | clinicaltrials |
| NCT00003855 | Lymph Node Removal in Treating Women Who Have Stage I or Stage IIA Breast Cancer | completed | Phase 3 | 605 | Alliance for Clinical Trials in OncologyOTHER | 4 | Apr 29, 2020 | clinicaltrials |
| NCT04031703 | Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN) | completed | Phase 3 | 647 | Fudan UniversityOTHER | 0 | Apr 24, 2020 | clinicaltrials |
| NCT03176238 | Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer(EVEREXES) | completed | Phase 3 | 235 | Novartis PharmaceuticalsINDUSTRY | 13 | Apr 7, 2020 | clinicaltrials |
| NCT00354302 | Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial | completed | Phase 3 | 497 | NCIC Clinical Trials GroupNETWORK | 1 | Apr 2, 2020 | clinicaltrials |
| NCT00002542 | Tamoxifen in Treating Women With High-Risk Breast Cancer | completed | Phase 3 | 672 | NCIC Clinical Trials GroupNETWORK | 1 | Apr 1, 2020 | clinicaltrials |
| NCT00002864 | Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer | completed | Phase 3 | 667 | NCIC Clinical Trials GroupNETWORK | 2 | Apr 1, 2020 | clinicaltrials |
| NCT00003032 | High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Metastatic or Recurrent Breast Cancer | completed | Phase 3 | 224 | NCIC Clinical Trials GroupNETWORK | 1 | Apr 1, 2020 | clinicaltrials |
| NCT02861859 | Individualised Versus Standard Care for Breast Cancer Patients at High-risk for Chemotherapy-induced Nausea and Vomiting The ILIAD Study | completed | Phase 3 | 221 | Ottawa Hospital Research InstituteOTHER | 1 | Feb 26, 2020 | clinicaltrials |
| NCT01099436 | Neo-Adjuvant Chemotherapy (TAC) With or Without Zoledronic Acid in Treating HER2-negative Breast Cancer Patients(NEO-ZOTAC) | completed | Phase 3 | 250 | Borstkanker Onderzoek GroepNETWORK | 1 | Jan 21, 2020 | clinicaltrials |
| NCT01935492 | 8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer(Stop&Go) | completed | Phase 3 | 420 | Borstkanker Onderzoek GroepNETWORK | 1 | Jan 18, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Jun 11, 2021source: clinicaltrials